Form 4: Madrigal Pharmaceuticals' Chief Medical Officer Receives Stock and Option Grants

David Soergel, Chief Medical Officer of Madrigal Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

Summary

• David Soergel, the Chief Medical Officer of Madrigal Pharmaceuticals, has reported changes in his beneficial ownership of the company's securities.
• On May 15, 2025, Soergel acquired 7,545 shares of common stock through a grant of restricted stock units.
• These restricted stock units vest in four equal installments on May 15 of 2026, 2027, 2028, and 2029, contingent upon his continued service with the company.
• Additionally, Soergel acquired options to purchase 12,839 shares of common stock at an exercise price of $291.82.
• These options vest 25% on May 15, 2026, and then 6.25% every three months thereafter, also contingent upon continued service.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. The sentiment is neutral to slightly positive.

Positives

• The grant of restricted stock units and stock options aligns the Chief Medical Officer's interests with those of the shareholders.
• The vesting schedules incentivize continued service and commitment to the company's long-term success.

Future Outlook

The vesting schedules for the restricted stock units and stock options extend over several years, indicating a long-term commitment from the Chief Medical Officer.

Industry Context

Stock grants and options are common forms of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value and incentivizing long-term performance.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Gilead Sciences, Amgen, and Regeneron also utilize stock options and restricted stock units to incentivize their executives.
• The vesting schedules are fairly typical, with vesting occurring over a period of 3-4 years, aligning with industry norms.

Stakeholder Impact

• Shareholders may view the stock and option grants positively as they incentivize management to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Madrigal Pharmaceuticals, MDGL, Form 4, Beneficial Ownership, David Soergel, Chief Medical Officer, Stock Options, Restricted Stock Units, Vesting